Could your own immune cells fight lung cancer? new trial tests safety

NCT ID NCT07202611

Recruiting now Disease control Sponsor: National Taiwan University Clinical Trial Center Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This Phase 2 trial is testing whether lab-grown immune cells (dendritic and natural killer cells) are safe for people with advanced non-small cell lung cancer. Ten participants will receive injections of their own cultured cells. The main goal is to check for side effects, not yet to see if it works.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: lab-grown dendritic cells and natural killer cells (immune cells)
What this could lead to: If it works, this could point toward a new immune-based treatment for advanced lung cancer that uses the patient's own cells.
What could go wrong: This is a very small, early Phase 2 trial focused on safety, not effectiveness. The treatment may not shrink tumors or improve survival, and side effects are unknown.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LUNG CANCER (NSCLC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

lung cancer lung neoplasm non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LUNG CANCER (NSCLC)

Contacts and locations

Locations

National Taiwan University Hospital Yunlin Branch
RECRUITING

Huwei, YUNLIN, 640, Taiwan

More trials for these conditions

Other studies related to the condition(s) this trial covers.